Celldex concludes Phase IIb enrolment for breast cancer drug

US-based Celldex Therapeutics has concluded patient enrolment in Phase IIb METRIC clinical trial of glembatumumab vedotin to treat metastatic triple negative breast cancer characterised by over-expression of gpNMB.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news